NCT04224415View on ClinicalTrials.gov

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

C225+CPT-11

"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT04224415 - Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC | Biotech Hunter | Biotech Hunter